European Union´s Horizon 2020 – Lipum2021-03-15T12:44:19+01:00


Novel Target for Treatment of Chronic Inflammatory Diseases — Notid

1709, 2020

Research engineer is strengthen our team

September 17th, 2020|

- It´s going to be both fun and exciting to contribute to Lipum's progress, says Assar Bäckman, research engineer. Assar comes with extensive experience in the field of gene expression analysis and he will strengthen our team in the lab during the autumn by further digging into BSSLs role in [...]

1808, 2020

Shareholders meeting in Lipum

August 18th, 2020|

News: Umeå, 18 August 2020. Lipum invites to a meeting with the shareholders On August 27, Lipum shareholders will meet virtually. The recent progress and plans for the future will be presented and discussed. More detailed information will be sent out in personal mail. Warm welcome!

1408, 2020


August 14th, 2020|

Pressmeddelande: Umeå, 17 August 2020. Kallelse till extra bolagsstämma Aktieägarna i Lipum AB, org. nr. 556813-5999 ("Lipum"), kallas härmed till extra bolagsstämma fredagen den 28 augusti 2020, kl. 12:00 på Tvistevägen 48C i Umeå. Förslag till dagordning och beslut bifogas. Handlingar enligt aktiebolagslagen (2005:551) skickas ut på begäran. Aktieägare som [...]

2707, 2020

Growing up with Juvenile Idiopathic Arthritis

July 27th, 2020|

Clara Laurell. Foto: Roger Larsson, Hallandsposten News: Umeå, 27 August 2020. Growing up with Juvenile Idiopathic Arthritis Every year, more than 200 Swedish children are diagnosed with Juvenile Idiopathic Arthritis (JIA), also called childhood rheumatism. JIA is a rheumatic disease that affects joints, causes severe pain and reduce the quality [...]

207, 2020

The founders want to improve patients’ quality of life

July 2nd, 2020|

Lipum is on a steady course towards clinical studies with its candidate for the treatment of juvenile idiopathic arthritis (SOL116). Previous we announced that the cell line was fully developed and was ready for the next step. BioStock has taken the opportunity to talk to one of our founders, Professor [...]

2406, 2020

Capital raise secures development of Lipum’s novel drug

June 24th, 2020|

Press release June 25, 2020 Lipum is supported by Horizon 2020, the EU framework program for research and development, and was granted 23 MSEK for the development of a biological pharmaceutical for treatment of chronic inflammatory diseases. In addition to this grant another 25 MSEK was raised in 2019. Now [...]

European Commission Horizon 2020
SME Instrument phase 1 No 744248
SME Instrument phase 2 No 829741

Project title:
Novel Target for Treatment of Chronic Inflammatory Diseases

Project budget:
3.2 M€

Funding from the EU:
2.2 M€



Go to Top